Mustang Bio has made progress in regulatory designations, Nasdaq compliance, capital raising, and operational restructuring during 2025 and early 2026.

• Mustang Bio received FDA Orphan Drug Designation for MB-108, an HSV-1 oncolytic virus for malignant glioma, in November 2024 and for MB-101, IL13Rα2-targeted CAR T-cells for recurrent glioblastoma and high-grade astrocytomas, in July 2025 [N1][N2].
• The company announced FDA acceptance of the IND application for MB-109, a combination therapy of MB-101 and MB-108, for treatment of IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma, with plans to initiate clinical trials potentially in Q2 2026 [N1][N2][S1].
• Mustang Bio completed a 1-for-50 reverse stock split in January 2025 to comply with Nasdaq listing requirements [N3][N4].
• The company exited its leased facility in Worcester, MA, and sold fixed assets to AbbVie for $1 million in early 2025, relocating its corporate headquarters to Waltham, MA [N5][N6].
• Mustang Bio completed a public offering in February 2025, raising approximately $8 million, and subsequent warrant exercises in July 2025 raised an additional $7.1 million, improving liquidity [N7][N8].
• The company regained compliance with Nasdaq listing requirements following recent public offerings and corporate actions [N3][N4][N7][N8].

Mustang Bio’s receipt of FDA Orphan Drug Designations for MB-101 and MB-108 supports the potential regulatory incentives and market exclusivity for these therapies targeting malignant brain tumors. The acceptance of the IND application for MB-109 and planned clinical trials indicate progress in clinical development. The company’s partnerships with City of Hope and Nationwide Children’s Hospital provide access to advanced research and clinical expertise. Recent capital raises and Nasdaq compliance actions improve its financial flexibility to advance its pipeline. If clinical trials demonstrate safety and efficacy, Mustang Bio could establish a differentiated position in the immunotherapy space for solid tumors.

Mustang Bio has no approved products and has incurred substantial operating losses since inception, with ongoing negative cash flows and an accumulated deficit nearing $399 million. The company’s ability to continue operations depends on raising additional capital, which may not be available on acceptable terms. Clinical development risks include potential delays, regulatory hurdles, and failure to demonstrate safety or efficacy. Manufacturing relies on third-party suppliers subject to regulatory compliance risks. The company faces cybersecurity risks and operational challenges related to its recent facility exit and asset divestment. Failure to secure funding or achieve regulatory milestones could materially impair its business and financial condition.

Mustang Bio’s moat is primarily based on its exclusive licenses to novel immunotherapy technologies developed by leading research institutions, including CAR T-cell therapy targeting IL13Rα2 and an oncolytic virus therapy. The FDA Orphan Drug Designations for its product candidates provide regulatory incentives such as market exclusivity and trial cost offsets. The company’s partnerships with reputable institutions and its focus on difficult-to-treat cancers contribute to its competitive positioning. However, as a clinical-stage company without approved products or commercial revenues, its moat is contingent on successful clinical development, regulatory approvals, and the ability to secure additional funding.

• Clinical Development Risk: The company’s product candidates are in early clinical stages with inherent risks of delays, failure to demonstrate safety or efficacy, and regulatory challenges that could impede development progress.
• Financial and Capital Risk: Mustang Bio has incurred significant losses and negative cash flows, requiring substantial additional funding to continue operations. Failure to raise capital on acceptable terms could lead to delays, scaling back, or termination of development programs.
• Manufacturing and Supply Chain Risk: The company relies on third-party manufacturers and suppliers subject to regulatory compliance and supply chain disruptions, which could delay clinical trials or commercialization.
• Regulatory Risk: Obtaining regulatory approvals is uncertain and may require additional studies or face delays, impacting the timing and feasibility of product commercialization.
• Cybersecurity Risk: The company faces risks from cyber-attacks or system failures that could disrupt operations or compromise sensitive information.
• Market and Listing Compliance Risk: Mustang Bio has taken corporate actions to regain Nasdaq compliance; failure to maintain listing standards could affect investor confidence and access to capital.

• Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, primarily solid tumors, through licensing and partnerships with research institutions such as City of Hope National Medical Center and Nationwide Children's Hospital [S1].
• The company’s pipeline includes MB-101, a CAR T therapy targeting IL13Rα2, and MB-108, a herpes simplex virus type 1 (HSV-1) oncolytic virus, intended to be combined as MB-109 for treatment of malignant brain tumors including glioblastoma and high-grade astrocytoma [S1].
• Phase 1 clinical trials for MB-101 and MB-108 have completed treatment phases, with ongoing long-term safety assessments [S1].
• The FDA accepted the IND application for MB-109 in October 2023, allowing initiation of a Phase 1 study for IL13Rα2+ recurrent glioblastoma and high-grade astrocytoma; the company is exploring conducting this trial as an investigator-sponsored single-institution study at City of Hope in Q2 2026 [S1].
• Mustang Bio received FDA Orphan Drug Designations for MB-108 (HSV-1 oncolytic virus) for malignant glioma in November 2024 and for MB-101 (IL13Rα2-targeted CAR T-cells) for recurrent diffuse and anaplastic astrocytoma and glioblastoma in July 2025 [S1][N1][N2].
• The company terminated the CD20 License with Fred Hutch in December 2025 due to unpaid patent expenses, with a mutual release and potential royalties on future licensing [S1].
• Mustang Bio has no approved products and has not generated revenue from product sales; it has incurred substantial operating losses since inception and expects to continue incurring losses [S1][S2].
• The company completed a 1-for-50 reverse stock split in January 2025 to comply with Nasdaq listing requirements [N3][N4].
• Mustang Bio exited its leased facility in Worcester, MA, and sold fixed assets to AbbVie for $1 million in early 2025, relocating its corporate headquarters to Waltham, MA [N5][N6].
• The company completed a public offering in February 2025, raising approximately $8 million, and subsequent warrant exercises in July 2025 raised an additional $7.1 million [N7][N8].
• As of December 31, 2025, Mustang Bio had cash and cash equivalents of approximately $17.3 million and current assets of $17.6 million, with current liabilities of $7.9 million, resulting in a current ratio of 2.22 and a cash ratio of 2.18 [S1].
• Net loss for the year ended December 31, 2025, was $1.9 million with basic and diluted EPS of -$0.39 [S1].
• The company has disclosed risks including cybersecurity threats, reliance on third-party manufacturers subject to regulatory compliance, potential delays in clinical trials, and the need for substantial additional funding to continue operations [S1][S2].
• Mustang Bio has regained compliance with Nasdaq listing requirements following recent public offerings and corporate actions [N3][N4][N7][N8].
• The company’s management and Audit Committee oversee cybersecurity risk management and technology strategy [S1].
• Mustang Bio retains all available funds and does not anticipate paying cash dividends in the foreseeable future [S1].